Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Equity Ratio (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Equity Ratio for 5 consecutive years, with 0.81 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 7.25% to 0.81 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.81 through Dec 2025, up 7.25% year-over-year, with the annual reading at 0.66 for FY2025, N/A changed from the prior year.
  • Equity Ratio for Q4 2025 was 0.81 at Neuphoria Therapeutics, up from 0.46 in the prior quarter.
  • The five-year high for Equity Ratio was 0.87 in Q2 2022, with the low at 0.46 in Q3 2025.
  • Average Equity Ratio over 4 years is 0.74, with a median of 0.76 recorded in 2023.
  • Peak annual rise in Equity Ratio hit 7.25% in 2025, while the deepest fall reached 38.58% in 2025.
  • Over 4 years, Equity Ratio stood at 0.87 in 2022, then fell by 11.55% to 0.77 in 2023, then dropped by 1.83% to 0.76 in 2024, then increased by 7.25% to 0.81 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.81, 0.46, and 0.66 for Q4 2025, Q3 2025, and Q2 2025 respectively.